This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Apr;7(4):287-289.

doi: 10.1016/S2213-2600(18)30503-4. Epub 2019 Jan 24.

The study of CFTR modulators in the very young

Patrick A Flume¹

Affiliations

PMID: 30686766
DOI: 10.1016/S2213-2600(18)30503-4

Comment

The study of CFTR modulators in the very young

Patrick A Flume. Lancet Respir Med. 2019 Apr.

. 2019 Apr;7(4):287-289.

doi: 10.1016/S2213-2600(18)30503-4. Epub 2019 Jan 24.

Author

Patrick A Flume¹

Affiliation

¹ Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, SC 29451, USA. Electronic address: flumepa@musc.edu.

PMID: 30686766
DOI: 10.1016/S2213-2600(18)30503-4

No abstract available

PubMed Disclaimer

Comment on

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS. McNamara JJ, et al. Lancet Respir Med. 2019 Apr;7(4):325-335. doi: 10.1016/S2213-2600(18)30460-0. Epub 2019 Jan 24. Lancet Respir Med. 2019. PMID: 30686767 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information